The drug is the only candidate to receive FDA breakthrough designation in the condition, and was granted the status based on phase 2 trial data from patients with IgA nephropathy and other kidney ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353 , 883–887 (1999). Article CAS Google Scholar ...

Your exact treatment plan will depend on the severity of your condition and the stage of IgAN you're in, but may include ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Renalys Pharma completes patient enrollment in registrational phase III trial of sparsentan for IgA nephropathy in Japan: Tokyo, Japan Friday, January 31, 2025, 18:00 Hrs [IST] Re ...

IgA nephropathy is typically a slowly progressing disease. How quickly kidney damage occurs can vary based on individual factors, including when you were diagnosed, the treatment you're receiving ...

Considering taking supplements to treat iga nephropathy? Below is a list of common natural remedies used to treat or reduce the symptoms of iga nephropathy. Follow the links to read common uses ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the ...

which will benefit more IgA nephropathy (IgAN) patients. NEFECON(R) was included in the NRDL in November 2024. As the first IgAN etiological treatment drug fully approved by the U.S. Food and Drug ...